BindRen: new phosphate binder

BindRen (colestilan) has been launched for the treatment of hyperphosphataemia in patient with stage 5 chronic kidney disease who are currently receiving dialysis.

BindRen granules are administered in three divided doses with meals


Colestilan is an anion exchange resin. It binds to phosphate in the gut but is not absorbed from the gastrointestinal tract, thereby increasing phosphate excretion. As colestilan may affect the bioavailability or absorption of other medicinal products, these should be taken at least 1 hour before or 3 hours after colestilan.1


Investigators assessed colestilan in three key placebo-controlled, phase III studies: two open-label flexible-dose studies in which they adjusted the colestilan dose according to phosphate levels and one fixed-dose study in which they randomised patients to receive 3g, 6g, 9g, 12g or 15g of colestilan per day or placebo.1,2

Significant phosphate lowering

In all studies, colestilan at a dose of at least 6g daily resulted in a significantly reduced blood phosphate level after 12 weeks of treatment compared with placebo. An average dose of 11.5g and 13.1g daily in the first and second flexible-dose studies reduced the blood phosphate level by 0.36mmol and 0.50mmol per litre, respectively.1,2

In the fixed-dose study, significant changes in blood phosphate levels were observed for patients who received at least 6g of colestilan daily compared with placebo. These changes were dose dependent.1,2

GI upset

Most adverse events in trials were gastrointestinal in origin, including nausea, vomiting, dyspepsia, constipation and haemorrhage.1,2


  1. BindRen Summary of Product Characteristics, August 2013.
  2. Locatelli F et al. Nephrol Dial Transplant 2013; 28: 1874–88.

View BindRen drug record

Further information: Mitsubishi Pharma

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...